Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
Breath of Life Recognizes the Emotional and Spiritual Calling of Respiratory Therapists Through a Faith-Centered Reflection Journal
Katherine Wilks Blends Faith, Family, Wellness, and Imagination Across a Diverse Collection of Inspirational and Family-Centered Books
Internet Freedom Foundation calls India’s BitChat GitHub takedown order ‘unconstitutional’
From high heels to ‘Zara death pants’: how fashion falls foul of women’s safety
Nvidia and Palantir urge US not to ban ‘open’ AI models after China scare
Crypto Biz: Is the AI-to-crypto rotation underway?
Meta faces higher borrowing costs in latest $12bn data centre financing
Burnham urged to lobby EU leaders directly to waive EES border controls
Silicon Valley Is Completely Divided Over Chinese AI
Dancing with Shakira at World Cup was ‘very, very, very, very, very good’ – Ghetto Kids
Meta glasses banned by Comic-Con promoter after ‘secret filming’
ALPHEA Secures $5M Strategic Funding
Summers Are Getting Hotter. Is Beauty Ready?
SHIBCAT Expands the Robinhood Chain Ecosystem with the Launch of Its Community-Driven Meme Token
Best Window Air Conditioners of 2026: Midea, Zafro, GE
Perfume Maker Givaudan’s Sales Beat Estimates, Tariff Paybacks Weigh on Shares
Cheval Collection wins prestigious Best Cross-Brand Contribution at Global Hotel Alliance Awards
Tolicious Secures Growth Investment from Mercia Ventures to Accelerate North East Expansion
IHG Hotels & Resorts to open first Kimpton in Indonesia
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.